Patheon's free-spending ways hurting investors, not managers
22nd Feb 2006, 13:49 GMT
Bay Street is a fickle beast, and Robert Tedford could tell you more about its capriciousness than most executives. Patheon, the drug manufacturer he runs, used to be one of the most beloved growth stories on the TSX, back in the 1990s when it could do no wrong. (INSIDER Edition subscribers only)
Patheon's free-spending ways hurting investors, not managers related news:
- Patheon shares fall on lower forecast — thestar.com: Business Top Stories
- Patheon stock drops on lower outlook — thestar.com: Breaking News
- Security Execs Push for Broader Use of Metrics — Computerworld Security News
- Rewarding Competitors Over Collaborators Doesn't Make Sense — ORNL in the News
- Investors Are Split on Digital Realty's Bet — WSJ.com: Markets
- Schroders buy adds to funds-of-hedge-funds spree — MarketWatch.com - Financial Services Industry News
- Oregon State forward Marcel Jones reacts after hurting himself ... — Sports Photos on Yahoo! News Photos
- Gartner warns IT managers to disable Google Desktop Search — GameSHOUT.com
- Hotel managers reconsider joining in contract negotiations — bizjournals.com Travel:Lodging & Conventions headlines
- State might cap new spending — Thestate.com: Metro